Results 241 to 250 of about 88,342 (327)

Computationally-designed aptamers targeting RAD51-BRCA2 interaction impair homologous recombination and induce synthetic lethality. [PDF]

Nat Commun
Milordini G, Zacco E, Masi M, Armaos A, Di Palma F, Oneto M, Gilodi M, Rupert J, Broglia L, Varignani G, Scotto M, Marotta R, Girotto S, Cavalli A, Tartaglia GG.   +14 more
europepmc   +1 more source

The Graphene Oxide Memristive DNA Sensor for Taxonomic Fingerprint

Macromolecular Materials and Engineering, EarlyView.
A graphene oxide–based memristive DNA sensor enables rapid, label‐free quantification of nucleotide base composition across 37%–55% GC with strong linear calibration. Delivering results within 2–5 min, the platform combines high sensitivity with minimal sample preparation, offering a practical tool for point‐of‐care diagnostics, genetic fingerprinting,
Konstantin G. Nikolaev, Jia Hui Bong, Siyu Chen, Kostya S. Novoselov, Daria V. Andreeva   +4 more
wiley   +1 more source

Innovative Applications of Nucleic Acid Aptamers in Colorectal Cancer Diagnosis and Therapy: From Selection Optimization to Clinical Translation. [PDF]

Int J Nanomedicine
Lu JF, Zhang XR, Liu Y, Zhang CL, Wang L, Liu ZQ, Cai J, Yi HW.   +7 more
europepmc   +1 more source

Nano Delivery Strategy Opens Effective Avenues for the Treatment of Colorectal Cancer

Medicine Bulletin, EarlyView.
ABSTRACT Colorectal cancer (CRC) presents significant therapeutic challenges because of chemoresistance, systemic toxicity, and the complexity of the tumor microenvironment (TME). Nanodrug delivery systems (NDDS) have emerged as versatile platforms capable of overcoming these limitations by enhancing tumor accumulation, improving pharmacokinetics, and ...
Qiurong Wei, Yunli Xu, Tianjiao Zhang, Shuyu Xu, Haonan Wang, Yuan Wang, Xinxin Xie, Xiaolong Liang   +7 more
wiley   +1 more source

Aptamer-Based Biosensors for Point-of-Care Diagnostics. [PDF]

Biosensors (Basel)
Díaz-Fernández A.
europepmc   +1 more source

Accelerating Medicines Partnership® Parkinson's Disease Proteomics: A Comprehensive Resource for Advancing Parkinson's Disease Research

Movement Disorders, EarlyView.
Abstract Background Recent advances in proteomic profiling have enabled its use as a powerful approach in elucidating molecular mechanisms underlying Parkinson's disease, enabling the identification of disease‐associated protein alterations and candidate biomarkers for diagnosis, progression, and therapeutic response.
Victoria J. Dardov, Aparna Vasanthakumar, Ameya Kulkarni, Niveda Sundararaman, Rakhi Pandey, Preeti Bais, Jennifer E. Van, Maria Quinton, Barry Landin, David Vismer, Bradford Casey, Matt Bookman, Willy Nojopranoto, Erin Teeple, Can Kayatekin, Rajaraman Krishnan, Richard Hargreaves, Guhan Nagappan, S. Pablo Sardi, Sri Ramulu Pullagura, Christine Swanson‐Fischer, Accelerating Medicines Partnership Parkinson's Disease (AMP PD) Proteomics Working Group   +21 more
wiley   +1 more source

Structure-enhanced deep learning accelerates aptamer selection for small molecule families like steroids. [PDF]

Brief Bioinform
Zhao Z, Lin H, Lau HY, Chen H, Hsing IM.
europepmc   +1 more source

Two‐Dimensional Transition Metal Dichalcogenides Properties Enhanced by Nano‐ and Micro‐Scale Shape Control

MetalMat, EarlyView.
This review explores current strategies for shaping two‐dimensional transition metal dichalcogenides (TMDs) beyond their planar form. It highlights how strain engineering, nanopatterning, and growth on complex substrates modulate their mechanical, optical, and electronic properties.
C. Grazianetti, G. Zambito, D. Campi, M. C. Giordano, F. Buatier de Mongeot, A. Molle, C. Martella   +6 more
wiley   +1 more source

Determining the Optimal Heparin Binding Domain Distance in VEGF₁₆₅ Using Umbrella Sampling Simulations for Optimal Dimeric Aptamer Design. [PDF]

Int J Mol Sci
Lee JS, Go YJ, Rhee YM.
europepmc   +1 more source

Enhancing Selective Brain Cancer Therapy: Integrating Nanomedicine and Molecular Dynamics to Target the Cancerous Lipid Composition

Nano Select, EarlyView.
Improving selectivity within therapeutic design is critical to ensure targeted delivery to brain tumors. Targeting the cellular membrane composition distinctive of the blood–brain barrier and brain cancer cells is explored in this review. Nanomedicine can be utilized for precise tumor recognition, and detailed mechanistic interactions of therapeutics ...
Mahnoor Kadri, Dominique de Jong‐Hoogland, Martin B. Ulmschneider   +2 more
wiley   +1 more source